Akari Therapeutics PLC (NASDAQ:AKTX)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.87 and traded as low as $2.05. Akari Therapeutics shares last traded at $2.07, with a volume of 1,528 shares.
Separately, Zacks Investment Research cut Akari Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, September 13th.
The business has a 50-day simple moving average of $1.87 and a two-hundred day simple moving average of $2.40. The company has a market cap of $33.14 million, a price-to-earnings ratio of -12.29 and a beta of -2.90.
About Akari Therapeutics (NASDAQ:AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.